Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	Golgi lumen	MUC19 MUC16 BCAN MUC12 MUC17 VCAN MUC4	1.56e-06	109	108	7	GO:0005796
Domain	DUF4927	NCOA2 NCOA3	2.84e-05	2	100	2	IPR032565
Domain	DUF4927	NCOA2 NCOA3	2.84e-05	2	100	2	PF16279
Domain	Pax2_C	PAX2 PAX5	8.48e-05	3	100	2	IPR022130
Domain	DUF1518	NCOA2 NCOA3	8.48e-05	3	100	2	PF07469
Domain	Nuc_rcpt_coact_Ncoa-typ	NCOA2 NCOA3	8.48e-05	3	100	2	IPR014920
Domain	SRC-1	NCOA2 NCOA3	8.48e-05	3	100	2	IPR014935
Domain	Pax2_C	PAX2 PAX5	8.48e-05	3	100	2	PF12403
Domain	Src1_rcpt_coact	NCOA2 NCOA3	8.48e-05	3	100	2	IPR008955
Domain	Nuclear_rcpt_coactivator	NCOA2 NCOA3	8.48e-05	3	100	2	IPR017426
Domain	-	NCOA2 NCOA3	8.48e-05	3	100	2	4.10.630.10
Domain	DUF1518	NCOA2 NCOA3	8.48e-05	3	100	2	IPR010011
Domain	DUF1518	NCOA2 NCOA3	8.48e-05	3	100	2	SM01151
Domain	SRC-1	NCOA2 NCOA3	8.48e-05	3	100	2	PF08832
Domain	Nuc_rec_co-act	NCOA2 NCOA3	8.48e-05	3	100	2	PF08815
Domain	Sushi	MASP1 BCAN VCAN SEZ6	1.72e-04	52	100	4	PF00084
Domain	CCP	MASP1 BCAN VCAN SEZ6	1.99e-04	54	100	4	SM00032
Domain	SEA	MUC16 MUC12 MUC17	2.13e-04	22	100	3	PF01390
Domain	SUSHI	MASP1 BCAN VCAN SEZ6	2.30e-04	56	100	4	PS50923
Domain	SEA	MUC16 MUC12 MUC17	2.44e-04	23	100	3	PS50024
Domain	SEA_dom	MUC16 MUC12 MUC17	2.44e-04	23	100	3	IPR000082
Domain	Sushi_SCR_CCP_dom	MASP1 BCAN VCAN SEZ6	2.46e-04	57	100	4	IPR000436
Domain	Nuc_rcpt_coact	NCOA2 NCOA3	4.20e-04	6	100	2	IPR009110
Domain	EGF_1	MASP1 BCAN MUC12 HMCN2 MUC17 VCAN MUC4	4.43e-04	255	100	7	PS00022
Domain	EGF-like_CS	MASP1 BCAN MUC12 HMCN2 MUC17 VCAN MUC4	5.09e-04	261	100	7	IPR013032
Domain	EGF_2	MASP1 BCAN MUC12 HMCN2 MUC17 VCAN MUC4	5.57e-04	265	100	7	PS01186
Domain	PAX	PAX2 PAX5	9.97e-04	9	100	2	SM00351
Domain	PAIRED_2	PAX2 PAX5	9.97e-04	9	100	2	PS51057
Domain	PAIRED_1	PAX2 PAX5	9.97e-04	9	100	2	PS00034
Domain	ENTH	PICALM EPN2	9.97e-04	9	100	2	PS50942
Domain	Paired_dom	PAX2 PAX5	9.97e-04	9	100	2	IPR001523
Domain	PAX	PAX2 PAX5	9.97e-04	9	100	2	PF00292
Domain	ENTH	PICALM EPN2	9.97e-04	9	100	2	SM00273
Domain	ENTH	PICALM EPN2	1.24e-03	10	100	2	IPR013809
Domain	EGF_3	MASP1 BCAN HMCN2 MUC17 VCAN MUC4	1.66e-03	235	100	6	PS50026
Domain	Link_dom	BCAN VCAN	2.13e-03	13	100	2	IPR000538
Domain	Xlink	BCAN VCAN	2.13e-03	13	100	2	PF00193
Domain	LINK_2	BCAN VCAN	2.13e-03	13	100	2	PS50963
Domain	LINK	BCAN VCAN	2.13e-03	13	100	2	SM00445
Domain	LINK_1	BCAN VCAN	2.13e-03	13	100	2	PS01241
Domain	EGF-like_dom	MASP1 BCAN HMCN2 MUC17 VCAN MUC4	2.22e-03	249	100	6	IPR000742
Domain	SEA	MUC16 MUC17	2.48e-03	14	100	2	SM00200
Domain	-	MUC16 MUC17	2.85e-03	15	100	2	3.30.70.960
Domain	VWF_type-D	MUC19 MUC4	3.24e-03	16	100	2	IPR001846
Domain	VWFD	MUC19 MUC4	3.24e-03	16	100	2	PS51233
Domain	VWD	MUC19 MUC4	3.24e-03	16	100	2	SM00216
Domain	VWD	MUC19 MUC4	3.24e-03	16	100	2	PF00094
Pathway	REACTOME_DEFECTIVE_GALNT3_CAUSES_HFTC	MUC16 MUC12 MUC17 MUC4	1.42e-06	16	77	4	M27410
Pathway	REACTOME_DEFECTIVE_C1GALT1C1_CAUSES_TNPS	MUC16 MUC12 MUC17 MUC4	1.86e-06	17	77	4	M27412
Pathway	REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	MUC19 MUC16 MUC17 MUC4	4.59e-06	21	77	4	MM15706
Pathway	REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS	MUC16 MUC12 MUC17 MUC4	6.73e-06	23	77	4	M556
Pathway	REACTOME_DECTIN_2_FAMILY	MUC16 MUC12 MUC17 MUC4	1.12e-05	26	77	4	M27483
Pathway	REACTOME_DISEASES_OF_METABOLISM	MUC16 BCAN MUC12 CD320 MUC17 VCAN MUC4 OPLAH	6.41e-05	250	77	8	M27554
Pathway	REACTOME_DISEASES_OF_GLYCOSYLATION	MUC16 BCAN MUC12 MUC17 VCAN MUC4	1.29e-04	143	77	6	M27275
Pathway	REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS	MUC19 MUC16 MUC17 MUC4	3.18e-04	60	77	4	MM15636
Pathway	REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS	MUC16 MUC12 MUC17 MUC4	3.61e-04	62	77	4	M546
Pathway	REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS	MUC16 MUC12 MUC17 MUC4	5.14e-04	68	77	4	M27303
Pubmed	Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux.	MUC19 MUC16 MUC12 OVGP1 MUC17 MUC4	1.57e-11	18	110	6	18834073
Pubmed	Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.	FOSB PAX2 PAX5	6.11e-07	6	110	3	22308434
Pubmed	Inducible NOS-induced chloride intracellular channel 4 (CLIC4) nuclear translocation regulates macrophage deactivation.	FOSB PAX2 PAX5	1.70e-06	8	110	3	22474389
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	CDK17 SHROOM3 UBAP2 MAP7D3 TRPM7 MAP4 MPDZ EPN2 MTMR4 ZFP36L1 CRYBG3 SIPA1L2 AHNAK2	3.49e-06	861	110	13	36931259
Pubmed	Adrenocorticotropic hormone-mediated signaling cascades coordinate a cyclic pattern of steroidogenic factor 1-dependent transcriptional activation.	NCOA2 NCOA3 KAT2A	4.99e-06	11	110	3	16109736
Pubmed	Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.	NCOA2 NCOA3 LANCL1 PWP1 KMT2D	5.07e-06	78	110	5	28611094
Pubmed	TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.	NCOA2 NCOA3 XRCC5 GMPS KMT2D PSPC1 SF3B2	6.75e-06	220	110	7	35785414
Pubmed	A novel p53 regulator, C16ORF72/TAPR1, buffers against telomerase inhibition.	UBAP2 NRL KAT2A PICALM GMPS SLC20A1 GMEB1 PAX2 SF3B2	9.76e-06	431	110	9	33660365
Pubmed	Nonsense mutation of the stereociliar membrane protein gene PTPRQ in human hearing loss DFNB84.	OTOGL PTPRQ	9.91e-06	2	110	2	20472657
Pubmed	Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis.	NCOA2 NCOA3	9.91e-06	2	110	2	21220509
Pubmed	Uterine Tumor Resembling Ovarian Sex Cord Tumor: A Distinct Entity Characterized by Recurrent NCOA2/3 Gene Fusions.	NCOA2 NCOA3	9.91e-06	2	110	2	30273195
Pubmed	Identification of two promoters for human D-amino acid oxidase gene: implication for the differential promoter regulation mediated by PAX5/PAX2.	PAX2 PAX5	9.91e-06	2	110	2	25500505
Pubmed	PAX2 promoter methylation and AIB1 overexpression promote tamoxifen resistance in breast carcinoma patients.	NCOA3 PAX2	9.91e-06	2	110	2	33509057
Pubmed	Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.	NCOA3 KAT2A	9.91e-06	2	110	2	32987137
Pubmed	Pax2 and homeodomain proteins cooperatively regulate a 435 bp enhancer of the mouse Pax5 gene at the midbrain-hindbrain boundary.	PAX2 PAX5	9.91e-06	2	110	2	10662641
Pubmed	A novel SRC-2-dependent regulation of epithelial-mesenchymal transition in breast cancer cells.	NCOA2 NCOA3	9.91e-06	2	110	2	30048685
Pubmed	Cloning of a mouse glucocorticoid modulatory element binding protein, a new member of the KDWK family.	NCOA2 GMEB1	9.91e-06	2	110	2	10692587
Pubmed	Immunocytochemistry for MUC4 and MUC16 is a useful adjunct in the diagnosis of pancreatic adenocarcinoma on fine-needle aspiration cytology.	MUC16 MUC4	9.91e-06	2	110	2	23544943
Pubmed	Diagnostic utility of PAX2 and PAX5 in distinguishing non-small cell lung cancer from small cell lung cancer.	PAX2 PAX5	9.91e-06	2	110	2	26823795
Pubmed	Differential proteoglycan expression in two spinal cord regions after dorsal root injury.	BCAN VCAN	9.91e-06	2	110	2	19683574
Pubmed	Effects of a Levonorgestrel-Releasing Intrauterine System on the Expression of Steroid Receptor Coregulators in Adenomyosis.	NCOA2 NCOA3	9.91e-06	2	110	2	26040939
Pubmed	Proteomic analysis of in vivo phosphorylated synaptic proteins.	SGIP1 MAP4 PKP4 SLC20A1	2.46e-05	53	110	4	15572359
Pubmed	Microbial products alter the expression of membrane-associated mucin and antimicrobial peptides in a three-dimensional human endocervical epithelial cell model.	MUC16 MUC4	2.97e-05	3	110	2	23053434
Pubmed	The transcriptional coregulators TIF2 and SRC-1 regulate energy homeostasis by modulating mitochondrial respiration in skeletal muscles.	NCOA2 NCOA3	2.97e-05	3	110	2	21035760
Pubmed	Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.	NCOA2 NCOA3	2.97e-05	3	110	2	21059860
Pubmed	Expression of mucin (MUC) genes in mucoepidermoid carcinoma.	MUC19 MUC4	2.97e-05	3	110	2	21072847
Pubmed	Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis.	NCOA2 NCOA3	2.97e-05	3	110	2	21735116
Pubmed	Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.	MUC16 MUC4	2.97e-05	3	110	2	30236127
Pubmed	Absence of the steroid receptor coactivator-3 induces B-cell lymphoma.	NCOA2 NCOA3	2.97e-05	3	110	2	16675958
Pubmed	FLASH interacts with p160 coactivator subtypes and differentially suppresses transcriptional activity of steroid hormone receptors.	NCOA2 NCOA3	2.97e-05	3	110	2	15698540
Pubmed	Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene.	NCOA2 NCOA3	2.97e-05	3	110	2	9506940
Pubmed	Steroid receptor coactivators present a unique opportunity for drug development in hormone-dependent cancers.	NCOA2 NCOA3	2.97e-05	3	110	2	28390937
Pubmed	Regulation of membrane-associated mucins in the human corneal epithelial cells by dexamethasone.	MUC16 MUC4	2.97e-05	3	110	2	17592322
Pubmed	Estrogen signaling in colorectal carcinoma microenvironment: expression of ERbeta1, AIB-1, and TIF-2 is upregulated in cancer-associated myofibroblasts and correlates with disease progression.	NCOA2 NCOA3	2.97e-05	3	110	2	19277704
Pubmed	Research resource: loss of the steroid receptor coactivators confers neurobehavioral consequences.	NCOA2 NCOA3	2.97e-05	3	110	2	23927929
Pubmed	Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.	MUC16 MUC12	2.97e-05	3	110	2	26770020
Pubmed	Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation.	NCOA2 NCOA3	2.97e-05	3	110	2	19052561
Pubmed	Two atypical enteropathogenic Escherichia coli strains induce the production of secreted and membrane-bound mucins to benefit their own growth at the apical surface of human mucin-secreting intestinal HT29-MTX cells.	MUC17 MUC4	2.97e-05	3	110	2	20065027
Pubmed	PAX immunoreactivity in poorly differentiated small round cell tumors of childhood.	PAX2 PAX5	2.97e-05	3	110	2	24897005
Pubmed	Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.	NCOA2 NCOA3	2.97e-05	3	110	2	18845648
Pubmed	The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP.	NCOA2 NCOA3	2.97e-05	3	110	2	12138202
Pubmed	Pax-5 is expressed at the midbrain-hindbrain boundary during mouse development.	PAX2 PAX5	2.97e-05	3	110	2	1283313
Pubmed	The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety.	BCAN VCAN	2.97e-05	3	110	2	9294172
Pubmed	Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection.	MUC16 MUC4	2.97e-05	3	110	2	35879412
Pubmed	The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1.	NCOA2 NCOA3	2.97e-05	3	110	2	11923473
Pubmed	Structure and chromosomal locations of mouse steroid receptor coactivator gene family.	NCOA2 NCOA3	2.97e-05	3	110	2	10501088
Pubmed	Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).	MUC16 MUC4	2.97e-05	3	110	2	27483328
Pubmed	MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.	MUC16 MUC4	2.97e-05	3	110	2	24204560
Pubmed	Expression of the transmembrane mucins, MUC1, MUC4 and MUC16, in normal endometrium and in endometriosis.	MUC16 MUC4	2.97e-05	3	110	2	24939955
Pubmed	The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism.	NCOA2 NCOA3	2.97e-05	3	110	2	16423883
Pubmed	New nomenclature for chromatin-modifying enzymes.	NCOA2 NCOA3 KAT2A KMT2D	3.29e-05	57	110	4	18022353
Pubmed	A probability-based approach for high-throughput protein phosphorylation analysis and site localization.	NCOA3 MAP4 ZC3HC1 NUP35 GMEB1 MASTL TLN2 LAS1L MRTFA	3.29e-05	503	110	9	16964243
Pubmed	Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.	NCOA2 NCOA3 KAT2A	3.93e-05	21	110	3	19596656
Pubmed	SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk.	NCOA3 MAP4 CIR1 XRCC5 PWP1 INTS6 TNRC18 LAS1L PSPC1 SF3B2	4.54e-05	655	110	10	35819319
Pubmed	cDNAs with long CAG trinucleotide repeats from human brain.	NCOA3 TNRC18 KMT2D	5.21e-05	23	110	3	9225980
Pubmed	Resolution of cell fate decisions revealed by single-cell gene expression analysis from zygote to blastocyst.	NCOA2 NCOA3 FOSB KAT2A ZBTB24 HMG20A ZFP36L1 GMEB1 PAX2 SF3B2 MRTFA	5.26e-05	808	110	11	20412781
Pubmed	Interactomes of Glycogen Synthase Kinase-3 Isoforms.	MAP7D3 MPDZ PICALM CRYBG3 SIPA1L2 CEP97	5.58e-05	209	110	6	36779422
Pubmed	miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.	NCOA2 NCOA3	5.92e-05	4	110	2	26066330
Pubmed	Id helix-loop-helix proteins antagonize pax transcription factor activity by inhibiting DNA binding.	PAX2 PAX5	5.92e-05	4	110	2	11134340
Pubmed	P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain.	NCOA2 NCOA3	5.92e-05	4	110	2	18267973
Pubmed	Selective recruitment of p160 coactivators on glucocorticoid-regulated promoters in Schwann cells.	NCOA2 NCOA3	5.92e-05	4	110	2	15331759
Pubmed	Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2.	NCOA2 NCOA3	5.92e-05	4	110	2	10598588
Pubmed	USP19 Suppresses Th17-Driven Pathogenesis in Autoimmunity.	NCOA3 USP19	5.92e-05	4	110	2	34135062
Pubmed	Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells.	NCOA2 NCOA3	5.92e-05	4	110	2	19462000
Pubmed	Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.	NCOA2 NCOA3	5.92e-05	4	110	2	19095746
Pubmed	Functional equivalence of the transcription factors Pax2 and Pax5 in mouse development.	PAX2 PAX5	5.92e-05	4	110	2	10934015
Pubmed	Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation.	NCOA2 NCOA3	5.92e-05	4	110	2	12893883
Pubmed	Estrogen receptor alpha/beta, AIB1, and TIF2 in colorectal carcinogenesis: do coregulators have prognostic significance?	NCOA2 NCOA3	5.92e-05	4	110	2	19198856
Pubmed	ADAMTS1, MPDZ, MVD, and SEZ6: candidate genes for autosomal recessive nonsyndromic hearing impairment.	MPDZ SEZ6	5.92e-05	4	110	2	34135477
Pubmed	Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy.	NCOA2 NCOA3	5.92e-05	4	110	2	22560224
Pubmed	NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer.	NCOA3 MUC4	5.92e-05	4	110	2	25531332
Pubmed	Interactions of RXR with coactivators are differentially mediated by helix 11 of the receptor's ligand binding domain.	NCOA2 NCOA3	5.92e-05	4	110	2	11851396
Pubmed	Two Pax-binding sites are required for early embryonic brain expression of an Engrailed-2 transgene.	PAX2 PAX5	5.92e-05	4	110	2	8625814
Pubmed	Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death.	NCOA2 NCOA3	5.92e-05	4	110	2	26267537
Pubmed	TRPV4 activation in human corneal epithelial cells promotes membrane mucin production.	MUC16 MUC4	5.92e-05	4	110	2	39024979
Pubmed	Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon.	MUC17 MUC4	5.92e-05	4	110	2	18198997
Pubmed	Lecticans: organizers of the brain extracellular matrix.	BCAN VCAN	5.92e-05	4	110	2	10766023
Pubmed	The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor.	NCOA2 NCOA3	5.92e-05	4	110	2	15563469
Pubmed	Nuclear hormone receptor coregulator GRIP1 suppresses, whereas SRC1A and p/CIP coactivate, by domain-specific binding of MyoD.	NCOA2 NCOA3	5.92e-05	4	110	2	15563453
Pubmed	Identification of novel Ack1-interacting proteins and Ack1 phosphorylated sites in mouse brain by mass spectrometry.	KIF21B SGIP1 MAP4 PKP4	6.23e-05	67	110	4	29254152
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	SHROOM3 UBAP2 DRAM1 YES1 ZNF804A PICALM TNRC18 MRTFA	6.98e-05	430	110	8	35044719
Pubmed	An organelle-specific protein landscape identifies novel diseases and molecular mechanisms.	NPHP1 CDK17 NCOA3 UBAP2 MAP7D3 ADRM1 EPN2 HMG20A TTC8 THADA RTL9 PTPRQ LAS1L CEP97	7.44e-05	1321	110	14	27173435
Pubmed	Transcription activation by the orphan nuclear receptor, chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI). Definition of the domain involved in the glucocorticoid response of the phosphoenolpyruvate carboxykinase gene.	NCOA2 NCOA3	9.85e-05	5	110	2	10652338
Pubmed	Redundant enhancement of mouse constitutive androstane receptor transactivation by p160 coactivator family members.	NCOA2 NCOA3	9.85e-05	5	110	2	17950690
Pubmed	SIP, a novel ankyrin repeat containing protein, sequesters steroid receptor coactivators in the cytoplasm.	NCOA2 NCOA3	9.85e-05	5	110	2	17476305
Pubmed	Ontogeny of steroid receptor coactivators in the hippocampus and their role in regulating postnatal HPA axis function.	NCOA2 NCOA3	9.85e-05	5	110	2	17854779
Pubmed	Dual role of the arginine methyltransferase CARM1 in the regulation of c-Fos target genes.	NCOA2 NCOA3	9.85e-05	5	110	2	18511550
Pubmed	Ligand-dependent contribution of RXRbeta to cholesterol homeostasis in Sertoli cells.	NCOA2 ABCA1	9.85e-05	5	110	2	14993927
Pubmed	Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment.	NCOA2 NCOA3	9.85e-05	5	110	2	14766010
Pubmed	The proteoglycans aggrecan and Versican form networks with fibulin-2 through their lectin domain binding.	BCAN VCAN	9.85e-05	5	110	2	11038354
Pubmed	Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.	NCOA2 NCOA3	9.85e-05	5	110	2	12714702
Pubmed	Regulation of transcription by a protein methyltransferase.	NCOA2 NCOA3	9.85e-05	5	110	2	10381882
Pubmed	Multifaceted transcriptional regulation of the murine intestinal mucus layer by endogenous microbiota.	MUC17 MUC4	9.85e-05	5	110	2	18035521
Pubmed	SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells.	NCOA2 NCOA3	9.85e-05	5	110	2	12514218
Pubmed	Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes.	NCOA2 NCOA3	9.85e-05	5	110	2	11376110
Pubmed	Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor.	NCOA2 NCOA3	9.85e-05	5	110	2	18798693
Pubmed	Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.	NCOA2 NCOA3	9.85e-05	5	110	2	12554772
Pubmed	Pax-2 expression in the murine neural plate precedes and encompasses the expression domains of Wnt-1 and En-1.	PAX2 PAX5	9.85e-05	5	110	2	7577673
Pubmed	SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4.	NCOA2 NCOA3	9.85e-05	5	110	2	9812974
Pubmed	p54nrb acts as a transcriptional coactivator for activation function 1 of the human androgen receptor.	NCOA2 PSPC1	9.85e-05	5	110	2	12810069
GeneFamily	CD molecules\|Mucins	MUC19 MUC16 MUC12 OVGP1 MUC17 MUC4	1.67e-10	21	72	6	648
GeneFamily	Zinc fingers ZZ-type\|Lysine acetyltransferases	NCOA2 NCOA3 KAT2A	3.96e-05	17	72	3	486
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	MASP1 BCAN VCAN SEZ6	7.79e-05	57	72	4	1179
GeneFamily	Hyalectan proteoglycans\|V-set domain containing\|Sushi domain containing\|C-type lectin domain containing	BCAN VCAN	9.34e-05	4	72	2	574
GeneFamily	Ataxins\|Trinucleotide repeat containing	NCOA3 TNRC18 KMT2D	1.31e-04	25	72	3	775
GeneFamily	Paired boxes	PAX2 PAX5	5.53e-04	9	72	2	675
GeneFamily	PDZ domain containing	SHROOM3 MPDZ SIPA1L2 AHNAK2	3.17e-03	152	72	4	1220
Coexpression	NABA_ECM_AFFILIATED	MUC19 MUC16 MUC12 OVGP1 MUC17 MUC4 PLXNB1	7.29e-06	170	109	7	M5880
CoexpressionAtlas	DevelopingGonad_e12.5_epididymis_emap-29139_k-means-cluster#5_top-relative-expression-ranked_500	TRPM7 MAP4 PKP4 GMPS TNRC18 GMEB1 CEP57	1.10e-05	150	107	7	gudmap_developingGonad_e12.5_epididymis_k5_500
ToppCell	Control-Myeloid-Macrophage\|Myeloid / Disease state, Lineage and Cell class	ABCA1 FOSB MAMLD1 PTGER2 ZFP36L1 VCAN DNAH6	5.25e-07	193	110	7	2a6d531abd34df20941cf3dac4fdfb1621a1bde6
ToppCell	3'-Broncho-tracheal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.3.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 ODAD4 SAMD15 CFAP74 DNAH6 MUC4	5.44e-07	194	110	7	4a2c127c90d1fefe604fcb9e796577d21b489dd6
ToppCell	5'-Adult-SmallIntestine-Epithelial-neuro-epithelial-EECs\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SGIP1 ZNF804A NYNRIN DNAH6 SLC29A4 SEZ6	3.12e-06	162	110	6	478cf560ef33c5c324142c76417447d4a571a2c9
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)\|390C / Donor, Lineage, Cell class and subclass (all cells)	UBR2 ABCA1 SHROOM3 UBAP2 NRL EPN2	8.78e-06	194	110	6	88db9f9e80c20ff3474f1f6459dcbdc25aec0b6d
ToppCell	390C-Epithelial_cells-Epithelial-I_(AT1)-\|390C / Donor, Lineage, Cell class and subclass (all cells)	UBR2 ABCA1 SHROOM3 UBAP2 NRL EPN2	8.78e-06	194	110	6	a71728202493d4858342ea2756ea281cd0d99a3a
ToppCell	COVID-19-Epithelial-Ciliated_cells\|COVID-19 / Condition, Lineage and Cell class	NPHP1 MUC16 ODAD4 CFAP74 DNAH6 MUC4	8.78e-06	194	110	6	43be5fbd51dd58839cb03ca3ddd05a458e1ddb74
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Multiciliated_(nasal)-Multiciliated_(nasal)_L.0.3.1.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 ODAD4 CFAP74 DNAH6 MUC4	9.04e-06	195	110	6	79dc031258579ea328181dda33710dd897f1064a
ToppCell	COVID-19-Epithelial\|COVID-19 / Condition, Lineage and Cell class	NPHP1 SHROOM3 MUC16 ODAD4 DNAH6 MUC4	9.58e-06	197	110	6	18fd7344628a87d5c7ef5efb66e260a4136245bf
ToppCell	COVID-19-kidney-Fibroblast-1\|kidney / Disease (COVID-19 only), tissue and cell type	ABCA1 COL15A1 SGIP1 MAMLD1 TWIST2 VCAN	1.01e-05	199	110	6	9503646ff1ad248181146ce767e9d12e882ec3bd
ToppCell	NS-moderate-d_16-33-Epithelial-unknown_epithelial\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MUC16 ERN2 INTS6 MUC4 PLXNB1	2.30e-05	137	110	5	03e124901a0e85b59b6882bbafab568b50907e8b
ToppCell	moderate-Epithelial-unknown_epithelial\|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	MUC16 ERN2 INTS6 MUC4 PLXNB1	2.39e-05	138	110	5	afefa8233c67aa744e939156bc538449bf6bd05b
ToppCell	NS-critical-d_07-13-Epithelial-unknown_epithelial\|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	MUC16 ERN2 INTS6 MUC4 PLXNB1	2.65e-05	141	110	5	33ad925ff7be3c682741a6328216a89f9d4033e9
ToppCell	Ionocyte-iono-3\|World / Class top	PROCA1 OVGP1 SYT11 MASTL XKR5	5.76e-05	166	110	5	9c4a780f8af46d7552077c7a0ae0ab1b2413e5d4
ToppCell	356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5\|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)	MPDZ THADA SYT11 TLN2 CEP57	6.27e-05	169	110	5	b66ffc2b2b6bfcc3a6e639d9d31d3de95f4a94e1
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 SHROOM3 MPDZ DNAH6 PLXNB1	6.63e-05	171	110	5	1854a777d9eb9d3fc3ed3632332a6f89ce8131da
ToppCell	tumor_Lymph_Node_/_Brain-B_lymphocytes-Undetermined\|B_lymphocytes / Location, Cell class and cell subclass	NPHP1 ELAPOR2 PTGER2 ZNF804A USP19	7.20e-05	174	110	5	390bd41ef114464f3db3e0cac4e67fe7571b4c23
ToppCell	3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MUC16 SPRED3 SLC20A1 MUC4 PLXNB1	7.20e-05	174	110	5	207aa0118633cbe9a65839bbb1bb3ba9f8118ad2
ToppCell	facs-Marrow-B-cells-24m\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MUC19 ZFP36L1 PTPRQ IGLL1 PAX5	7.40e-05	175	110	5	887e75fc90e59a6394d62f3c048a9cfdf6707725
ToppCell	facs-Marrow-B-cells-24m-Lymphocytic\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MUC19 ZFP36L1 PTPRQ IGLL1 PAX5	7.60e-05	176	110	5	c6484334187f64cd00cd35e77d8ae436556b4260
ToppCell	5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.0.3\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	MAP7D3 ZNF804A GMPS INTS6 NAPRT	7.81e-05	177	110	5	68f1139fc378f351e3b9e9f392aacb150025bf03
ToppCell	nucseq-Epithelial-Epithelial_Glandular\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 ERN2 MUC17 MUC4 AHNAK2	8.23e-05	179	110	5	859cd8ee414ad6207c046ada2e655e49322dd01c
ToppCell	droplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte-type_1_alveolar_epithelial_cell\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ELAPOR2 BCAN PMEL SPRED3 OVGP1	8.23e-05	179	110	5	ca70a5518c5a5392e088c103e0cb44aa084f5332
ToppCell	droplet-Lung-3m-Epithelial-alveolar_epithelial-type_I_pneumocyte\|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	ELAPOR2 BCAN PMEL SPRED3 OVGP1	8.23e-05	179	110	5	c451b074b04eb5d6c575c6abaedda579c6744bbf
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ABCA1 COL15A1 HMCN2 VCAN XKR5	8.45e-05	180	110	5	f2f6e83127a4a415e65c76a35efa8175fbd5b5d9
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Hematopoietic-B_cells\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	SPN IGKV2D-30 IGLL1 PAX5 IGKV2-30	8.45e-05	180	110	5	36e8606893cfb055d38f5a76a8f0c5e1742f3df7
ToppCell	nucseq-Epithelial-Epithelial_Glandular-Goblet\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 ERN2 MUC17 MUC4 AHNAK2	8.45e-05	180	110	5	3dc80bc636bf0e6ffc9762853132a9fe59fd1f66
ToppCell	nucseq-Epithelial-Epithelial_Glandular-Goblet-Goblet\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	MUC16 ERN2 MUC17 MUC4 AHNAK2	8.45e-05	180	110	5	668a2d8e1d5a390309d5eb62c836f5903144bea9
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	COL15A1 TWIST2 HMCN2 OSBP2 AHNAK2	8.67e-05	181	110	5	3462aa1c08fbaf613b6278ab2c7a5a0940bf537d
ToppCell	PND14-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_mature\|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	COL15A1 TWIST2 HMCN2 OSBP2 AHNAK2	8.67e-05	181	110	5	6730e249cac55ae892cc567d9211615882f3dab4
ToppCell	cellseq2-Immune-Lymphocytic_T/NK-Lymphocytic_T/NK-NK\|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NRL MUC12 PTGER2 PSMG3-AS1 SPRED3	8.90e-05	182	110	5	8ccffcbae28c374fd4161fb0d4cf2c49fae557f6
ToppCell	Control-Epithelial_cells-Airway_mucous\|Control / group, cell type (main and fine annotations)	MUC16 ERN2 MUC17 SIPA1L2 MUC4	9.13e-05	183	110	5	15d24a4fb1ffe6cbafbd54fcd7dde9ddcfbe03b2
ToppCell	COVID-19-Epithelial_cells-Airway_ciliated\|COVID-19 / group, cell type (main and fine annotations)	NPHP1 MUC16 ODAD4 CFAP74 DNAH6	9.61e-05	185	110	5	18a40f0a338aa398d81384b5159fb80ce8a2020c
ToppCell	NS-critical-d_16-33-Epithelial-Ciliated\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	NPHP1 MPDZ SAMD15 CFAP74 DNAH6	9.86e-05	186	110	5	76033438426d8f9c72cd6691a7baf92104c9f03d
ToppCell	Smart-seq2-blood_(Smart-seq2)-myeloid-myeloid_monocytic-classical_monocyte\|blood_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	MUC19 MUC16 ZFP36L1 OTOGL VCAN	9.86e-05	186	110	5	23b8d51d20b05795a73892d3e20e0f9b6a207820
ToppCell	5'-Airway_Nasal-Endothelial-Blood_vessel_EC-vein_endothelial_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF21B COL15A1 PKP4 YES1 SIPA1L2	1.04e-04	188	110	5	524d1d928c9386acf20e53d31894107dd7290dc7
ToppCell	5'-Airway_Nasal-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic-EC_venous_systemic_L.2.2.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF21B COL15A1 PKP4 YES1 SIPA1L2	1.04e-04	188	110	5	1b57995d70cf81212e8d46dfaf44dbaf9c7bc4d5
ToppCell	5'-Airway_Nasal-Endothelial-Blood_vessel_EC\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF21B COL15A1 PKP4 YES1 SIPA1L2	1.04e-04	188	110	5	cd2d1f8e43c252dd8730a5758458ef63e7ffc836
ToppCell	5'-Airway_Nasal-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_systemic\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF21B COL15A1 PKP4 YES1 SIPA1L2	1.04e-04	188	110	5	f5a2f324f3f6c5078d57130392d3f1ba74f29094
ToppCell	5'-Airway_Nasal-Endothelial\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	KIF21B COL15A1 PKP4 YES1 SIPA1L2	1.04e-04	188	110	5	6c9d5e4014f807149328ff4eabd5e86dfe18094d
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast-\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CDK17 SGIP1 FOSB MAMLD1 TWIST2	1.09e-04	190	110	5	1121eb607a984c59fbffe7220837fc178745aa55
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Mesenchymal-Fibroblast-Collagen-low_Matrisome-low_fibroblast\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	CDK17 SGIP1 FOSB MAMLD1 TWIST2	1.09e-04	190	110	5	048b581e3f7ea9fc2f87c0532974bba85c7292c2
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Deuterosomal-Deuterosomal_L.0.3.4.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 MUC12 SAMD15 MUC4	1.09e-04	190	110	5	0adb24dafa077156bbc73a8d8cbf3d9eeb6e08df
ToppCell	(1)_Control_(PBS)-(3)_LEPR+_perivascular_cells\|World / Stress and Cell class	SHROOM3 FOSB MPDZ ZFP36L1 TLN2	1.09e-04	190	110	5	ec0ab31266583a0966ac7615d5c0fabb7b7e66e8
ToppCell	3'-Airway_Nasal-Epithelial-Airway_ciliated-multi-ciliated_epithelial_cell-Deuterosomal\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 MUC12 SAMD15 MUC4	1.09e-04	190	110	5	05455775845f4ded5c27e7b83242078d23162aaf
ToppCell	Control-Epithelial-Ciliated_cells\|Control / Condition, Lineage and Cell class	MUC16 CFAP74 MUC4 PLXNB1 AHNAK2	1.12e-04	191	110	5	ea1d2c6838119b7019e9a2ff71d6212262b51b57
ToppCell	Control-Epithelial\|Control / Condition, Lineage and Cell class	MUC16 CFAP74 MUC4 PLXNB1 AHNAK2	1.12e-04	191	110	5	6228302febdb3dffe37dece7062d27ac9ccc6d4b
ToppCell	nucseq\|World / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	NCOA2 ABCA1 PICALM MRTFA RNF111	1.17e-04	193	110	5	779276e775cb2492e8dd36436295a536084a6415
ToppCell	Club_cells-Myositis-ILD_01\|World / lung cells shred on cell class, cell subclass, sample id	MUC16 ERN2 ZFP36L1 NYNRIN MUC4	1.17e-04	193	110	5	6582c0367052b9d10fb629c383ee0c55872afd2d
ToppCell	Control-Myeloid-MoAM5,_CCL3L1\|Myeloid / Condition, Lineage and Cell class	ABCA1 LILRB2 FOSB PTGER2 ZFP36L1	1.20e-04	194	110	5	96400477d130b2403ed81c229e4e4182cc2cdc14
ToppCell	BAL-Control-Myeloid-MoAM\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	ABCA1 LILRB2 FOSB ZFP36L1 VCAN	1.20e-04	194	110	5	a4523adbbd25c314809eed3414d66a5b323446e5
ToppCell	COVID-19-Heart-Fib_2\|Heart / Disease (COVID-19 only), tissue and cell type	COL15A1 TWIST2 HMCN2 SLC20A1 VCAN	1.20e-04	194	110	5	d91c9f2ec47319051fc398320693fddbe8bbd4d6
ToppCell	BAL-Control-Myeloid-MoAM\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	ABCA1 LILRB2 FOSB ZFP36L1 VCAN	1.20e-04	194	110	5	125bf2909cf89133693bc7b865ca08955cf67a2e
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic-neutrophil\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	SHROOM3 MUC19 MUC16 HMCN2 OTOGL	1.23e-04	195	110	5	d3755929ebbbf5e3afde44281e9056ddb614a291
ToppCell	Smart-seq2-spleen_(Smart-seq2)-myeloid-myeloid_granulocytic\|spleen_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	SHROOM3 MUC19 MUC16 HMCN2 OTOGL	1.23e-04	195	110	5	19853c654ac64b3ae3bc99841c6cb29c8aaba85c
ToppCell	5'-Adult-LargeIntestine\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	FOSB MUC12 SLC20A1 MUC4 IGKV2-30	1.23e-04	195	110	5	600174e35574fe7c44dd923adcf43686e7b01e39
ToppCell	3'-GW_trimst-2-LargeIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL15A1 DRAM1 FOSB PTGER2 VCAN	1.26e-04	196	110	5	a7adc0e0baef261d0937e4e8351321d41beca82f
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_naive-G\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	LILRB2 FOSB PTGER2 ZFP36L1 VCAN	1.26e-04	196	110	5	f811958823380069077754283e36106d80147494
ToppCell	Tracheal-NucSeq-Epithelial-Epi_airway_secretory\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MUC16 ERN2 KCNQ3 FAM83D MUC4	1.26e-04	196	110	5	b07db4a53ab9be9aad6fae5e45f9547db829d096
ToppCell	5'-Adult-LargeIntestine-Mesenchymal-fibroblastic-Stromal_1_(CCL11+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ABCA1 COL15A1 SGIP1 VCAN CRYBG3	1.26e-04	196	110	5	2ab9735aa7a7e95dcf6b0bdf0427f7b57f6349ee
ToppCell	Tracheal-NucSeq-Epithelial-Epi_airway_secretory-Secretory_Goblet\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MUC16 ERN2 KCNQ3 FAM83D MUC4	1.26e-04	196	110	5	c366f980cc04abfe1c0c14746c11810c812a42c0
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 ODAD4 DNAH6 MUC4	1.29e-04	197	110	5	91637bdeab85024b5a02d1066f76cb803a2d6420
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 ODAD4 DNAH6 MUC4	1.29e-04	197	110	5	22c87dd15dc57bd0aa98a204c9fc9b3b9b573b45
ToppCell	3'-Parenchyma_lung-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.2.2\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MPDZ ODAD4 CFAP74 DNAH6	1.29e-04	197	110	5	74a2c6cb8fcfe53dd9a2b36492a16c58f38e51c9
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)-Multiciliated_(non-nasal)_L.0.3.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 ODAD4 DNAH6 MUC4	1.29e-04	197	110	5	3bbf068d2ad8196fbc85d3f311a7c54c9aece856
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL15A1 SGIP1 TWIST2 BCAN VCAN	1.29e-04	197	110	5	44673c38384453207871d3fd8e8ba9093cc06bc5
ToppCell	5'-Airway_Nasal-Epithelial-Airway_ciliated-ciliated_columnar_cell_of_tracheobronchial_tree-Multiciliated_(non-nasal)\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	NPHP1 MUC16 ODAD4 DNAH6 MUC4	1.29e-04	197	110	5	87db09f341e2b20eb6e1c3e917cb5c960387b3e9
ToppCell	Bronchus_Control_(B.)\|World / Sample group, Lineage and Cell type	MUC16 ERN2 INTS6 PAX5 MUC4	1.29e-04	197	110	5	b6dff2ee108813e18657e2d8cf850e2423f8c8e9
ToppCell	Control-Stromal-Fibroblast\|Stromal / Disease state, Lineage and Cell class	ABCA1 DRAM1 FOSB TWIST2 VCAN	1.29e-04	197	110	5	64cc5f61c88e9560b0f8f6f3151255dffb5c3d66
ToppCell	Tracheal-NucSeq-Epithelial-Epi_airway_ciliated-Deuterosomal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	NPHP1 ODAD4 SAMD15 CFAP74 DNAH6	1.32e-04	198	110	5	f31790442ef142f1c0c49bf3daf2d0efb193d2c9
ToppCell	Parenchymal-NucSeq-Epithelial-Epi_airway_secretory\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	SHROOM3 PKP4 ERN2 ZFP36L1 MUC4	1.32e-04	198	110	5	af399569c718f5fd971d73a7926768c9311002a3
ToppCell	severe-HLA-DR+_CD83+_Monocyte\|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	LILRB2 FOSB ZFP36L1 MUC17 VCAN	1.32e-04	198	110	5	a77f3440d7fb6a50066abc7e9ad59e83798ef13d
ToppCell	Non-neuronal-Dividing-Radial_Glia-vRG-20\|World / Primary Cells by Cluster	SHROOM3 FOSB BCAN ZFP36L1 SYT11	1.32e-04	198	110	5	bce0bc1e3f2257e0f42a1fa6e5b57cf71e4514ba
ToppCell	Severe_COVID-19\|World / Disease group,lineage and cell class （2021.01.30）	LILRB2 FOSB PTGER2 ZFP36L1 VCAN	1.32e-04	198	110	5	09fd456077bb3a657ad3b10c6cfe799b7266456a
ToppCell	BAL-Severe\|BAL / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	LILRB2 FOSB PTGER2 ZFP36L1 VCAN	1.32e-04	198	110	5	454aee3f4fe6d0beeccc55200b4495f4f9b44feb
ToppCell	BAL-Severe\|BAL / Location, Disease Group, Cell group, Cell class (2021.03.09)	LILRB2 FOSB PTGER2 ZFP36L1 VCAN	1.32e-04	198	110	5	687f69c16343227854c882b4a0f3930ce534a3d2
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_1_(ADAMDEC1+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	COL15A1 DRAM1 PTGER2 ZNF804A VCAN	1.35e-04	199	110	5	bdedcc7c8f3be0996200c882dda82fb2658655c0
ToppCell	Lung_Parenchyma-Severe\|Lung_Parenchyma / Location, Disease Group, Cell group, Cell class (2021.03.09)	ABCA1 FOSB MUC16 ZFP36L1 MUC4	1.38e-04	200	110	5	62502bb23ca732daed32c838ce9719093f3aaeb0
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	COL15A1 SGIP1 TWIST2 ADGRG4 VCAN	1.38e-04	200	110	5	3dd022e974fec7013ba18f333da63f58fbf2dd7c
ToppCell	TCGA-Ovary-Primary_Tumor\|TCGA-Ovary / Sample_Type by Project: Shred V9	PKP4 NYNRIN GMEB1 PSPC1	1.39e-04	106	110	4	14f548be39cec604fbdae0382cbf434fa4049840
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma\|TCGA-Ovary / Sample_Type by Project: Shred V9	PKP4 NYNRIN GMEB1 PSPC1	1.39e-04	106	110	4	939b80950d39cdc7149a05fdfb64c8810064cdb1
ToppCell	TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma\|TCGA-Ovary / Sample_Type by Project: Shred V9	PKP4 NYNRIN GMEB1 PSPC1	1.39e-04	106	110	4	e9e1b55f32b3d5b9eeec94a997912e5c21c1fb48
Drug	Cimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A	NCOA2 ABCA1 SPN POM121L2 ERN2 NYNRIN METTL16 AHNAK2	3.53e-06	192	107	8	4144_DN
Drug	Suramin sodium salt; Down 200; 10uM; PC3; HT_HG-U133A	SPN PKP4 PTGER2 USP19 NYNRIN GMEB1 MUC4 MRTFA	3.81e-06	194	107	8	7529_DN
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	NCOA2 MAP4 PKP4 MPDZ POM121L2 EPN2 OVGP1 VCAN	4.11e-06	196	107	8	2687_DN
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Down 200; 13.2uM; MCF7; HT_HG-U133A	NCOA2 SPN MAP4 PKP4 USP19 GMEB1 TLN2 CEP97	4.27e-06	197	107	8	1470_DN
Drug	Sulfaphenazole [526-08-9]; Up 200; 12.8uM; HL60; HT_HG-U133A	COL15A1 MAP7D3 SPN LILRB2 ERN2 ZFP36L1 KCNQ3 MRTFA	4.43e-06	198	107	8	1836_UP
Drug	Ketoprofen [22071-15-4]; Up 200; 15.8uM; PC3; HT_HG-U133A	MAP7D3 PKP4 BCAN ERN2 NYNRIN VCAN KCNQ3 OSBP2	4.43e-06	198	107	8	4286_UP
Drug	Edrophonium chloride [116-38-1]; Up 200; 19.8uM; MCF7; HT_HG-U133A	NCOA2 SPN MAP4 USP19 OVGP1 CEP97 MRTFA AHNAK2	4.43e-06	198	107	8	1519_UP
Drug	2-propylpentanoic acid; Down 200; 500uM; HL60; HT_HG-U133A	NCOA2 COL15A1 SPN MAP4 MPDZ POM121L2 VCAN METTL16	4.43e-06	198	107	8	2700_DN
Drug	Hydroxytacrine maleate (R,S) [118909-22-1]; Down 200; 12.2uM; HL60; HT_HG-U133A	MAP7D3 MAP4 PKP4 POM121L2 ERN2 OVGP1 VCAN	3.72e-05	194	107	7	2430_DN
Drug	PNU-0251126 [267429-19-6]; Down 200; 10uM; PC3; HT_HG-U133A	CDK17 NCOA3 ABCA1 LANCL1 PICALM SYT11 VCAN	3.72e-05	194	107	7	3689_DN
Drug	Thalidomide [50-35-1]; Down 200; 15.4uM; MCF7; HT_HG-U133A	NCOA2 MAP7D3 MAP4 RALGPS1 GMEB1 PAX5 CEP57	3.97e-05	196	107	7	2258_DN
Drug	Medrysone [2668-66-8]; Up 200; 11.6uM; PC3; HT_HG-U133A	KIF21B MAP7D3 SPN LILRB2 ERN2 PAX2 PAX5	4.10e-05	197	107	7	4266_UP
Drug	Coralyne chloride hydrate [38989-38-7]; Down 200; 9.6uM; PC3; HT_HG-U133A	NCOA2 CDK17 ABCA1 MPDZ KIAA1549L SYT11 GMEB1	4.10e-05	197	107	7	6317_DN
Drug	Gelsemine [509-15-9]; Down 200; 12.4uM; PC3; HT_HG-U133A	SPN LILRB2 BCAN NYNRIN TLN2 OSBP2 PLXNB1	4.10e-05	197	107	7	4097_DN
Drug	Ajmalicine hydrochloride [4373-34-6]; Down 200; 10.2uM; PC3; HT_HG-U133A	SPN MAP4 CIR1 PICALM OVGP1 SYT11 GMEB1	4.10e-05	197	107	7	6360_DN
Drug	Remoxipride Hydrochloride [73220-03-8]; Up 200; 9.8uM; MCF7; HT_HG-U133A	SPN MAP4 LILRB2 CIR1 NYNRIN OSBP2 AHNAK2	4.23e-05	198	107	7	6503_UP
Drug	Oxethazaine [126-27-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A	MAP7D3 BCAN OVGP1 ZFP36L1 RALGPS1 VCAN PAX5	4.23e-05	198	107	7	1484_UP
Drug	Nitrendipine [39562-70-4]; Down 200; 11uM; MCF7; HT_HG-U133A	NCOA2 SPN MAP4 ZNF804A EPN2 GMEB1 PLXNB1	4.23e-05	198	107	7	5405_DN
Drug	Ofloxacin [82419-36-1]; Down 200; 11uM; MCF7; HT_HG-U133A	LILRB2 CIR1 PMEL ERN2 USP19 OVGP1 TLN2	4.23e-05	198	107	7	4696_DN
Drug	BAS 012416453; Down 200; 38uM; MCF7; HT_HG-U133A	CIR1 ERN2 ZFP36L1 GMEB1 PAX2 PAX5 MRTFA	4.23e-05	198	107	7	6880_DN
Drug	Famprofazone [22881-35-2]; Down 200; 10.6uM; HL60; HT_HG-U133A	ABCA1 MAP7D3 LILRB2 LANCL1 CD320 ERN2 SYT11	4.37e-05	199	107	7	2174_DN
Drug	estradiol, USP; Down 200; 0.01uM; MCF7; HT_HG-U133A	CIR1 ERN2 ZNF804A USP19 ZFP36L1 RALGPS1 MRTFA	4.37e-05	199	107	7	5601_DN
Drug	AC1MHEDP	FOSB YES1 IGLL1 PAX5	1.96e-04	61	107	4	CID003002894
Drug	Trichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A	KIF21B MAP4 PMEL SYT11 RALGPS1 AHNAK2	2.03e-04	179	107	6	6993_UP
Drug	trichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A	KIF21B PMEL OVGP1 SYT11 RALGPS1 AHNAK2	2.23e-04	182	107	6	7043_UP
Drug	trichostatin A, Streptomyces sp.; Up 200; 1uM; MCF7; HT_HG-U133A	KIF21B PMEL OVGP1 SYT11 RALGPS1 AHNAK2	2.50e-04	186	107	6	7499_UP
Drug	Quercetine dihydrate [6151-25-3]; Up 200; 11.8uM; HL60; HT_HG-U133A	ABCA1 FOSB BCAN OVGP1 TLN2 PAX2	2.73e-04	189	107	6	2499_UP
Drug	Dimethisoquin hydrochloride [2773-92-4]; Up 200; 13uM; MCF7; HT_HG-U133A	NRL FOSB PICALM OVGP1 MRTFA AHNAK2	2.89e-04	191	107	6	4791_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A	NCOA2 ERN2 ZNF804A THADA OVGP1 MRTFA	2.97e-04	192	107	6	2450_DN
Drug	0317956-0000 [391210-11-0]; Down 200; 1uM; PC3; HT_HG-U133A	NCOA2 SPN PICALM VCAN PLXNB1 MRTFA	2.97e-04	192	107	6	4334_DN
Drug	Clomiphene citrate (Z,E) [50-41-9]; Down 200; 6.6uM; MCF7; HT_HG-U133A	SPN MAP4 ERN2 EPN2 RALGPS1 METTL16	2.97e-04	192	107	6	2624_DN
Drug	Felodipine [72509-76-3]; Down 200; 10.4uM; HL60; HT_HG-U133A	ABCA1 MAP4 FOSB LANCL1 KAT2A OVGP1	3.14e-04	194	107	6	2433_DN
Drug	Norcyclobenzaprine [303-50-4]; Down 200; 15.4uM; HL60; HT_HG-U133A	ABCA1 LILRB2 POM121L2 OVGP1 VCAN MRTFA	3.14e-04	194	107	6	2469_DN
Drug	Acyclovir [59277-89-3]; Up 200; 17.8uM; PC3; HG-U133A	MAP4 PKP4 PICALM THADA OVGP1 LAS1L	3.22e-04	195	107	6	1960_UP
Drug	prochlorperazine dimaleate salt; Up 200; 10uM; HL60; HT_HG-U133A	NCOA2 NCOA3 SPN MAP4 ZFP36L1 SYT11	3.22e-04	195	107	6	1156_UP
Drug	Sulfamethoxypyridazine [80-35-3]; Down 200; 14.2uM; MCF7; HT_HG-U133A	SPN MAP4 EPN2 THADA TLN2 CEP97	3.22e-04	195	107	6	3409_DN
Drug	Tiapride hydrochloride [51012-33-0]; Down 200; 11uM; PC3; HT_HG-U133A	CDK17 PKP4 OVGP1 RALGPS1 METTL16 MRTFA	3.22e-04	195	107	6	3663_DN
Drug	Azathymine, 6 [932-53-6]; Down 200; 31.4uM; MCF7; HT_HG-U133A	NCOA2 SPN MAP4 EPN2 OVGP1 PLXNB1	3.22e-04	195	107	6	4106_DN
Drug	Daunorubicin hydrochloride [23541-50-6]; Up 200; 7uM; MCF7; HT_HG-U133A	PMEL CD320 SYT11 OSBP2 PAX2 PLXNB1	3.22e-04	195	107	6	4983_UP
Drug	Melatonin [73-31-4]; Up 200; 17.2uM; PC3; HT_HG-U133A	SPN KAT2A ERN2 PICALM USP19 METTL16	3.22e-04	195	107	6	6293_UP
Drug	Streptozotocin [18883-66-4]; Down 200; 15uM; MCF7; HT_HG-U133A	SPN BCAN USP19 METTL16 CEP97 MRTFA	3.22e-04	195	107	6	6098_DN
Drug	rofecoxib; Up 200; 10uM; MCF7; HG-U133A	CDK17 SPN POM121L2 ERN2 PAX2 CEP57	3.22e-04	195	107	6	166_UP
Drug	butamben	NCOA2 NCOA3	3.24e-04	6	107	2	ctd:C004605
Drug	Chrysin [480-40-0]; Up 200; 15.8uM; HL60; HT_HG-U133A	NPHP1 ABCA1 MPDZ BCAN OVGP1 PAX2	3.31e-04	196	107	6	3106_UP
Drug	Phensuximide [86-34-0]; Up 200; 21.2uM; PC3; HT_HG-U133A	ERN2 ZFP36L1 RALGPS1 VCAN TLN2 PAX5	3.31e-04	196	107	6	5097_UP
Drug	Fluvoxamine maleate [61718-82-9]; Up 200; 9.2uM; HL60; HT_HG-U133A	MASP1 LILRB2 FOSB MPDZ ST7L SYT11	3.31e-04	196	107	6	2913_UP
Drug	Levonordefrin [829-74-3]; Up 200; 21.8uM; MCF7; HT_HG-U133A	NCOA2 ERN2 RALGPS1 NYNRIN KCNQ3 MRTFA	3.31e-04	196	107	6	7208_UP
Drug	Levonordefrin [829-74-3]; Down 200; 21.8uM; HL60; HT_HG-U133A	SPN MAP4 LILRB2 CD320 ERN2 TLN2	3.31e-04	196	107	6	2710_DN
Drug	Methimazole [60-56-0]; Up 200; 35uM; HL60; HT_HG-U133A	MAP4 LILRB2 PKP4 ST7L VCAN TLN2	3.31e-04	196	107	6	2570_UP
Drug	Parbendazole [14255-87-9]; Down 200; 16.2uM; MCF7; HT_HG-U133A	CIR1 ERN2 USP19 OVGP1 TLN2 PAX5	3.31e-04	196	107	6	3881_DN
Drug	6-Hydroxytropinone [5932-53-6]; Up 200; 25.8uM; MCF7; HT_HG-U133A	MAP4 OVGP1 ZFP36L1 GMEB1 PAX2 MRTFA	3.31e-04	196	107	6	7346_UP
Drug	Metampicillin sodium salt [6489-61-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A	NCOA2 ABCA1 MAMLD1 LANCL1 ERN2 PAX5	3.31e-04	196	107	6	5540_DN
Drug	Lomefloxacin hydrochloride [98079-52-8]; Up 200; 10.4uM; PC3; HT_HG-U133A	SPN ERN2 USP19 NYNRIN VCAN PAX2	3.31e-04	196	107	6	4281_UP
Drug	Trichlorfon [52-68-6]; Up 200; 15.6uM; MCF7; HT_HG-U133A	NRL SPN KMT2D PAX2 METTL16 MUC4	3.31e-04	196	107	6	5989_UP
Drug	Minoxidil [38304-91-5]; Down 200; 19.2uM; HL60; HG-U133A	MAP7D3 SPN BCAN HMG20A GMEB1 CEP57	3.31e-04	196	107	6	1996_DN
Drug	PNU-0251126 [267429-19-6]; Down 200; 10uM; MCF7; HT_HG-U133A	SPN PMEL ERN2 ZNF804A EPN2 PAX2	3.31e-04	196	107	6	4711_DN
Drug	Sisomicin sulfate [53179-09-2]; Down 200; 2.8uM; HL60; HT_HG-U133A	NCOA2 LILRB2 CD320 EPN2 VCAN MRTFA	3.31e-04	196	107	6	2493_DN
Drug	Alcuronium chloride [15180-03-7]; Down 200; 5.4uM; MCF7; HT_HG-U133A	NCOA2 SPN ERN2 ZNF804A EPN2 GMEB1	3.31e-04	196	107	6	4409_DN
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HG-U133A	ABCA1 SPN MAP4 HMG20A THADA VCAN	3.40e-04	197	107	6	1732_DN
Drug	rofecoxib; Down 200; 10uM; HL60; HG-U133A	KIF21B MASP1 SPN MAP4 PICALM KMT2D	3.40e-04	197	107	6	371_DN
Drug	0316684-0000 [391209-55-5]; Up 200; 10uM; MCF7; HT_HG-U133A	MAP4 ZNF804A ZFP36L1 NYNRIN PLXNB1 MRTFA	3.40e-04	197	107	6	7052_UP
Drug	Mesalamine [89-57-6]; Down 200; 26.2uM; MCF7; HT_HG-U133A	CDK17 MAP4 LILRB2 USP19 EPN2 PLXNB1	3.40e-04	197	107	6	3584_DN
Drug	Cyclopentolate hydrochloride [5870-29-1]; Up 200; 12.2uM; PC3; HT_HG-U133A	NPHP1 LILRB2 PKP4 POM121L2 ZFP36L1 METTL16	3.40e-04	197	107	6	5734_UP
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; PC3; HT_HG-U133A	ABCA1 SPN USP19 OVGP1 VCAN OSBP2	3.40e-04	197	107	6	4547_DN
Drug	Ribavirin [36791-04-5]; Down 200; 16.4uM; MCF7; HT_HG-U133A	CIR1 OVGP1 ZFP36L1 TLN2 PAX5 MRTFA	3.40e-04	197	107	6	6018_DN
Drug	Nadide [53-84-9]; Up 200; 6uM; MCF7; HT_HG-U133A	MAP4 LILRB2 KMT2D OSBP2 MUC4 PLXNB1	3.40e-04	197	107	6	6091_UP
Drug	Niacin [59-67-6]; Down 200; 32.4uM; HL60; HT_HG-U133A	ABCA1 MAP4 THADA ZFP36L1 VCAN CEP97	3.40e-04	197	107	6	3043_DN
Drug	PF-00562151-00 [351320-12-2]; Up 200; 10uM; PC3; HT_HG-U133A	NCOA2 ABCA1 ERN2 GMEB1 TLN2 MRTFA	3.40e-04	197	107	6	6863_UP
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; MCF7; HT_HG-U133A	NCOA2 CDK17 MAP7D3 SPN ERN2 CEP97	3.40e-04	197	107	6	2643_DN
Drug	Cinchonine [118-10-5]; Down 200; 13.6uM; HL60; HT_HG-U133A	SPN MAP4 FOSB CD320 EPN2 VCAN	3.40e-04	197	107	6	2133_DN
Drug	Aminohippuric acid [61-78-9]; Down 200; 20.6uM; MCF7; HT_HG-U133A	SPN MAP4 LANCL1 BCAN RALGPS1 PLXNB1	3.40e-04	197	107	6	6453_DN
Drug	Deltaline [6836-11-9]; Down 200; 7.8uM; MCF7; HT_HG-U133A	ABCA1 PMEL OVGP1 ZFP36L1 RALGPS1 MRTFA	3.40e-04	197	107	6	3831_DN
Drug	Trioxsalen [3902-71-4]; Down 200; 17.6uM; MCF7; HT_HG-U133A	NCOA2 MAP4 ERN2 ZFP36L1 GMEB1 PAX5	3.40e-04	197	107	6	6078_DN
Drug	felodipine; Up 200; 10uM; MCF7; HG-U133A	MASP1 SPN KAT2A ST7L KMT2D ZFP36L1	3.40e-04	197	107	6	337_UP
Drug	PNU-0230031 [267429-39-0]; Up 200; 10uM; MCF7; HT_HG-U133A	NRL SPN LILRB2 PMEL PAX2 PAX5	3.40e-04	197	107	6	4754_UP
Drug	Idoxuridine [54-42-2]; Down 200; 11.2uM; HL60; HG-U133A	CDK17 NCOA3 MAP7D3 SPN HMG20A CEP57	3.40e-04	197	107	6	1980_DN
Drug	Droperidol [548-73-2]; Up 200; 10.6uM; PC3; HT_HG-U133A	LILRB2 ERN2 GMEB1 TLN2 PAX2 PAX5	3.40e-04	197	107	6	4629_UP
Drug	Sulfacetamide sodic hydrate [6209-17-2]; Up 200; 15.8uM; MCF7; HT_HG-U133A	SPN MAP4 ERN2 NYNRIN PAX5 PLXNB1	3.40e-04	197	107	6	1695_UP
Drug	Dilazep dihydrochloride [20153-98-4]; Down 200; 6uM; HL60; HT_HG-U133A	SPN MAP4 PICALM USP19 SYT11 VCAN	3.50e-04	198	107	6	2333_DN
Drug	Tocopherol (R,S) [10191-41-0]; Down 200; 9.2uM; HL60; HT_HG-U133A	NCOA3 SPN MAP4 LANCL1 KAT2A ERN2	3.50e-04	198	107	6	1320_DN
Drug	Chloroquine diphosphate [50-63-5]; Down 200; 7.8uM; PC3; HT_HG-U133A	ABCA1 SPN MPDZ ERN2 ZNF804A THADA	3.50e-04	198	107	6	7251_DN
Drug	Furaltadone hydrochloride [3759-92-0]; Up 200; 11uM; PC3; HT_HG-U133A	NPHP1 FOSB PKP4 ERN2 SYT11 KCNQ3	3.50e-04	198	107	6	3756_UP
Drug	Ethambutol dihydrochloride [1070-11-7]; Up 200; 14.4uM; HL60; HG-U133A	NCOA3 PKP4 CIR1 KAT2A OVGP1 CFAP74	3.50e-04	198	107	6	1981_UP
Drug	Benzocaine [94-09-7]; Down 200; 24.2uM; MCF7; HT_HG-U133A	SPN MAP4 CIR1 PMEL TLN2 CEP97	3.50e-04	198	107	6	4808_DN
Drug	Dequalinium dichloride [522-51-0]; Up 200; 7.6uM; PC3; HT_HG-U133A	PMEL USP19 ZFP36L1 KCNQ3 METTL16 MRTFA	3.50e-04	198	107	6	6296_UP
Drug	Iocetamic acid [16034-77-8]; Down 200; 6.6uM; PC3; HT_HG-U133A	SPN CIR1 ERN2 OVGP1 PLXNB1 MRTFA	3.50e-04	198	107	6	4600_DN
Drug	Xylazine [7361-61-7]; Up 200; 18.2uM; MCF7; HT_HG-U133A	KIF21B NRL ZFP36L1 VCAN PAX5 MRTFA	3.50e-04	198	107	6	4147_UP
Drug	Demeclocycline hydrochloride [64-73-3]; Down 200; 8uM; PC3; HT_HG-U133A	NCOA2 NPHP1 ERN2 KIAA1549L SYT11 TLN2	3.50e-04	198	107	6	3706_DN
Drug	Griseofulvin [126-07-8]; Up 200; 11.2uM; HL60; HT_HG-U133A	EPN2 MTMR4 SYT11 VCAN GMEB1 MRTFA	3.50e-04	198	107	6	2332_UP
Drug	Famprofazone [22881-35-2]; Up 200; 10.6uM; PC3; HT_HG-U133A	LILRB2 PMEL SYT11 RALGPS1 KCNQ3 PLXNB1	3.50e-04	198	107	6	3753_UP
Drug	Racecadotril [81110-73-8]; Down 200; 10.4uM; HL60; HG-U133A	UBR2 CDK17 MAP7D3 SPN MAP4 LAS1L	3.59e-04	199	107	6	1782_DN
Drug	Cytisine (-) [485-35-8]; Up 200; 21uM; HL60; HG-U133A	NCOA3 SPN MAP4 PKP4 BCAN PICALM	3.59e-04	199	107	6	1766_UP
Drug	Diflunisal [22494-42-4]; Down 200; 16uM; PC3; HT_HG-U133A	SPN KIAA1549L VCAN METTL16 PLXNB1 MRTFA	3.59e-04	199	107	6	4210_DN
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	UBAP2 PMEL ERN2 OVGP1 TLN2 PAX5	3.59e-04	199	107	6	4843_DN
Drug	SC 19220; Down 200; 10uM; MCF7; HT_HG-U133A	MAP7D3 SPN MAP4 EPN2 THADA PAX5	3.59e-04	199	107	6	7090_DN
Drug	Niflumic acid [4394-00-7]; Down 200; 14.2uM; HL60; HT_HG-U133A	MAP4 ERN2 USP19 SYT11 VCAN METTL16	3.59e-04	199	107	6	2399_DN
Drug	Nimodipine [66085-59-4]; Down 200; 9.6uM; MCF7; HT_HG-U133A	CDK17 ABCA1 BCAN ZNF804A OVGP1 MRTFA	3.59e-04	199	107	6	6480_DN
Drug	THIP Hydrochloride; Up 200; 22.6uM; MCF7; HT_HG-U133A	KIF21B POM121L2 PMEL ERN2 VCAN AHNAK2	3.59e-04	199	107	6	6511_UP
Drug	Acemetacin [53164-05-9]; Down 200; 9.6uM; PC3; HT_HG-U133A	NCOA3 SPN MAP4 LANCL1 EPN2 VCAN	3.59e-04	199	107	6	6361_DN
Drug	Lasalocid sodium salt [25999-20-6]; Down 200; 6.6uM; MCF7; HT_HG-U133A	NCOA2 SPN ERN2 EPN2 RALGPS1 CEP97	3.59e-04	199	107	6	4985_DN
Disease	Bicuspid aortic valve	HMCN2 MUC4	3.90e-05	3	107	2	HP_0001647
Disease	mean arterial pressure	SGIP1 MAP4 PKP4 ST7L YES1 THADA ZFP36L1 PAX2 SEZ6	8.72e-05	499	107	9	EFO_0006340
Disease	interleukin-6 measurement, response to stimulus	ELAPOR2 MUC16	7.01e-04	11	107	2	EFO_0004810, GO_0050896
Disease	intracranial aneurysm (is_implicated_in)	KMT2D VCAN	8.40e-04	12	107	2	DOID:10941 (is_implicated_in)
Disease	Bardet-Biedl syndrome (is_implicated_in)	NPHP1 TTC8	1.15e-03	14	107	2	DOID:1935 (is_implicated_in)
Disease	Ischemic stroke	NCOA2 ELAPOR2 MPDZ PICALM TTC8 NYNRIN	1.19e-03	324	107	6	HP_0002140
Disease	cholangiocarcinoma (is_marker_for)	MUC16 OSBP2 MUC4	1.64e-03	64	107	3	DOID:4947 (is_marker_for)
Disease	1-Methylhistidine measurement	NCOA2 OTOGL	1.71e-03	17	107	2	EFO_0021543
Disease	neuroimaging measurement	KIF21B SHROOM3 UBAP2 DRAM1 BCAN ST7L THADA RALGPS1 VCAN TLN2 CEP57	1.74e-03	1069	107	11	EFO_0004346
Disease	Alzheimer disease	ABCA1 LILRB2 PICALM TLN2 PAX2 PAX5 SIPA1L2	1.97e-03	485	107	7	MONDO_0004975
Disease	citrulline measurement	LANCL1 HMCN2	2.37e-03	20	107	2	EFO_0009777
Disease	seborrheic dermatitis	ELAPOR2 TNRC18	2.37e-03	20	107	2	EFO_1000764
Disease	Endometrioma	PTGER2 SLC20A1 VCAN PAX2	2.85e-03	161	107	4	C0269102
Disease	Endometriosis	PTGER2 SLC20A1 VCAN PAX2	2.85e-03	161	107	4	C0014175
Disease	Sjogren's syndrome (is_marker_for)	MUC19 MUC16	3.41e-03	24	107	2	DOID:12894 (is_marker_for)

Protein segments in the cluster

Peptide	Gene	Start	Entry
AASTGPGMEPETTAT	PKP4	21	Q99569
TTSPSSPEEDVMLGS	SYT11	146	Q9BT88
DPPTLASRSAGITGM	nan	61	Q8N976
PSALPGIDVGSSVMS	VCAN	2846	P13611
NFSISPPTFVSGVGM	CRYBG3	651	Q68DQ2
TPSLEMTDTGFPETT	ADGRG4	1291	Q8IZF6
TLGGITTGFPTSLPM	ADGRG4	2076	Q8IZF6
SSFPGISIMESPLES	MASTL	571	Q96GX5
TTMSILTGLFPPTSG	ABCA1	941	O95477
LGDMPFVAGKSTSPS	CEP57	286	Q86XR8
FSEEMSSGLESPTGP	RALGPS1	406	Q5JS13
PGTMSVESEQLTGVP	INTS6	176	Q9UL03
ESGFTMPPSEGTQLV	KAT2A	376	Q92830
TLTGMVPGSEFSGSP	PAX5	331	Q02548
TGTTPPESGIFGFMI	DRAM1	46	Q8N682
TQSMVPPTGFSEEEG	BCAN	436	Q96GW7
TGFTETPEGSASPSM	MUC16	2956	Q8WXI7
ITTTVGDPAPSTSMP	MUC16	5156	Q8WXI7
TTPPVEETSSGFSLM	MUC16	5621	Q8WXI7
AEMTIPTQTGPSGST	MUC16	7026	Q8WXI7
DTAPSMVTSPGVDTR	MUC16	11601	Q8WXI7
TLAGSLFTPLTTPGM	MUC16	11996	Q8WXI7
NPGETSSVPVTGSLM	MUC4	276	Q99102
PGSSGDVVMTQSPLS	IGKV2D-30	16	A0A075B6S6
SAAPTFMISPETVTG	MAP4	616	P27816
SSGVPGAMSPEQTLF	PSMG3-AS1	176	Q96PY0
PDTPFSLFEGMAGTI	LANCL1	366	O43813
SPITITPVGQSFSMG	GMEB1	406	Q9Y692
GSMFLPPTTVAGATL	GHITM	261	Q9H3K2
GTSGPPVTMATDSLE	SPN	181	P16150
TGPPVTMTTGSLEPS	SPN	201	P16150
VLTSSFASMPLPGSG	HMG20A	291	Q9NP66
STSFGPGPGVESMAV	EPN2	576	O95208
GTVMPPTTGDATLAF	HMCN2	26	Q8NDA2
GDATTMGPPVTLESV	CD320	176	Q9NPF0
GETQMTLTTEGPSTP	ERN2	141	Q76MJ5
TPSGSMPLSSTGDGI	KCNQ3	846	O43525
ATVPATTFPGAMGSV	PLXNB1	821	O43157
RPLGETTGTTIPSME	MUC19	2361	Q7Z5P9
IPSMEGSEATGPSVI	MUC19	2371	Q7Z5P9
PGESPAISSVMFSAG	PTGER2	21	P43116
TQTEPGEEMPGLSVS	FAM83D	391	Q9H4H8
PPMLDSGAEVSASTT	KIF21B	841	O75037
PTFSEPGMVGATEGT	NRL	51	P54845
SEPLELVVSGPSMGS	LILRB2	411	Q8N423
PPSSVNTGGITEIMA	METTL16	206	Q86W50
MEVGPFSTGQESPTA	LAS1L	606	Q9Y4W2
GSSTPGFLSPMAELS	KIAA1549L	41	Q6ZVL6
EMASGRPLFPGSTVE	CDK17	381	Q00537
PLGVPMSGTGTTSSA	OSBP2	161	Q969R2
FKPPTSMTGATGSEL	ELAPOR2	496	A8MWY0
QGMVTSFPSGEATPR	MTMR4	911	Q9NYA4
PVVTGRDMASTTLPG	PAX2	326	Q02962
ISVSAFTIMGEGPPT	PTPRQ	586	Q9UMZ3
GLGEMPGSFVPTVTA	FOSB	46	P53539
PLVFILSTGSDPMGA	DNAH6	3541	Q9C0G6
ADGTPITQGVEMTTP	IGLL1	151	P15814
ITSDFMTGIPATPGN	GMPS	641	P49915
AFADGRGTTESMPSP	LINC02876	11	F2Z3M2
SESTFMPVASGLSPL	CEP97	401	Q8IW35
MASSSPGATEPFTFG	MAMLD1	526	Q13495
GVGMAPEVSTDSFPV	MAP7D3	326	Q8IWC1
TPGQEVVLSPGSFMS	MASP1	101	P48740
PGSSGDVVMTQSPLS	IGKV2-30	16	P06310
EASSVPTGGPTLSMS	COL15A1	376	P39059
PVPPTETMSEVSGAT	SAMD15	161	Q9P1V8
TMGKDLTPITPSSGF	SLC20A1	586	Q8WUM9
VGPATASPDLGTSMA	PROCA1	191	Q8NCQ7
GTSMATGTPDSTAPI	PROCA1	201	Q8NCQ7
GSEDASPMGPTSFEF	CFAP74	1061	Q9C0B2
TTMGAIPAGFRPSTL	NPHP1	321	O15259
PSDITVFDMLTPTTG	OTOGL	1456	Q3ZCN5
SVGESPGPFVDMGTL	NYNRIN	236	Q9P2P1
SPGGTTMTPVHFQTE	OVGP1	541	Q12889
VTSTPGTGQSMFSPA	NUP35	126	Q8NFH5
TAEGSSMPTSTPGER	MUC17	2676	Q685J3
TAEGTSMPISTPGER	MUC17	2971	Q685J3
TAGEGSTPLTNMPVS	MUC17	3511	Q685J3
SDPGGTSTQLMTSPV	RTL9	56	Q8NET4
DGTSSALSMGPFVPF	THADA	1336	Q6YHU6
VSGLSAGMSIIPTFP	SLC18B1	341	Q6NT16
MSDPEGETLRSTFPS	ODAD4	1	Q96NG3
PMDTFSGSSAVLSGP	OPLAH	276	O14841
VTASPSMDGLLAGPT	NCOA3	1286	Q9Y6Q9
EFMDTTGERSPSPLT	SIPA1L2	1641	Q9P2F8
KGSEAESTPPSFMSV	SHROOM3	1606	Q8TF72
PEGPDASSIMSTESI	PMEL	436	P40967
TPGDTFGEMVTSPLT	MRTFA	471	Q969V6
DMSPTSGAFSIGALP	POM121L2	911	Q96KW2
TISDFMSPGPTDLLS	ARNTL	11	O00327
PSFGMLSPGKSIEVS	AHNAK2	4471	Q8IVF2
MTTSGALFPSLVPGS	ADRM1	1	Q16186
INASSVPTDGSGPSM	CIR1	151	Q86X95
VTSVPTSGLSSMGPE	NCOA2	1416	Q15596
GGIMTAPAIDIFSTP	PICALM	366	Q13492
SMGTGDTPGLEVPSS	ZC3HC1	381	Q86WB0
ISGPFGSRSSDTPME	PWP1	486	Q13610
YEPTTGMIFSTDGVP	TNRC18	2951	O15417
ITPGGFSSVPAGMET	SF3B2	746	Q13435
GGSPTTFLFRPMSES	ZFP36L1	271	Q07352
PVSSSESAPGTIMNG	UBAP2	631	Q5T6F2
GPVPSTSGISSEMLA	USP19	936	O94966
LGTASMLTSPDGPFI	TTC8	161	Q8TAM2
TPSVDISMGPASGFT	MPDZ	916	O75970
TTSSAVTETGPPAMP	RNF111	461	Q6ZNA4
SRTGSETPQAPMSGV	PSPC1	481	Q8WXF1
SAGDPPVTAMSSVET	SAGE2P	506	A6NJ88
TFEGSSRGPSPLTMG	SGIP1	541	Q9BQI5
IITMESASGFGPTTP	SPRED3	166	Q2MJR0
MAVPTLGPGEIASTT	SEZ6	161	Q53EL9
PLMGGTESSISEPGS	ST7L	121	Q8TDW4
VTSFSGSEVPPDPML	NAPRT	216	Q6XQN6
MPGPSQGISIVTAES	ZBTB24	566	O43167
ALPAVMRSGSSGPET	TLN2	451	Q9Y4G6
GTPDPGVVMSFTFDS	SLC29A4	16	Q7RTT9
FPDTMADISPILGTG	XKR5	591	Q6UX68
SPTSPVAETEGTIME	UBR2	1006	Q8IWV8
MPSEEGTLNGLTSPF	TRPM7	1531	Q96QT4
VGFTMSNSIPGIESP	XRCC5	16	P13010
SLSMTPFGGSSGVTP	YES1	56	P07947
ETVCAPGSGPMFKST	ZNF804A	126	Q7Z570
MEEGSSSPVSPVDSL	TWIST2	1	Q8WVJ9
IGTTPESMATEPGEV	KMT2D	4051	O14686
SPISSGSMETTALPG	MUC12	611	Q9UKN1
TTAFPGSTTMPGLSQ	MUC12	676	Q9UKN1
SPISSGSMETTALPG	MUC12	941	Q9UKN1
TTAFPGSTTMPGVSQ	MUC12	1731	Q9UKN1
METTALPGSTTTPGL	MUC12	2031	Q9UKN1
THTTAFPGSTTMPGV	MUC12	3286	Q9UKN1
FPGSTTMPGVSQEST	MUC12	3291	Q9UKN1
SPISSGSMETTALPG	MUC12	3581	Q9UKN1
METTALPGSTTTPGL	MUC12	4671	Q9UKN1